Trial Profile

A Phase I, Single-Center, Open-Label Study to Evaluate Pharmacodynamics of Drug-Drug Interaction Between SHR4640 and Febuxostat in Patients With Hyperuricemia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Febuxostat (Primary) ; Ruzinurad (Primary)
Indications Hyperuricaemia
Focus Pharmacokinetics
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

12 Sep 2022 Results comparing febuxostat or SHR4640 pharmacokinetic and pharmacodynamic parameters, and safety and tolerability, published in the Journal of Clinical Pharmacology.
12 Nov 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com